img

Global Haemophilia Treatment Industry Research Report, Growth Trends and Competitive Analysis 2024-2034


Published on: 2024-01-04 | No of Pages : 400 | Industry : Pharma & Healthcare

Publisher : MRA | Format : PDF

Global Haemophilia Treatment Industry Research Report, Growth Trends and Competitive Analysis 2024-2034

Haemophilia is a mostly inherited genetic disorder that impairs the body's ability to make blood clots, a process needed to stop bleeding.
The global Haemophilia Treatment market size was US$ million in 2022 and is forecast to a readjusted size of US$ million by 2034 with a CAGR of % during the forecast period 2024-2034.
The United States market for Haemophilia Treatment is estimated to increase from $ million in 2024 to reach $ million by 2034, at a CAGR of % during the forecast period of 2024 through 2034.
The China market for Haemophilia Treatment is estimated to increase from $ million in 2024 to reach $ million by 2034, at a CAGR of % during the forecast period of 2024 through 2034.
The Europe market for Haemophilia Treatment is estimated to increase from $ million in 2024 to reach $ million by 2034, at a CAGR of % during the forecast period of 2024 through 2034..
The global key manufacturers of Haemophilia Treatment include Bayer, Novo Nordisk, Pfizer, Roche, Aptevo Therapeutics, Catalyst BioSciences, Dimension Therapeutics, Takeda and CSL Behring, etc. In 2022, the global top five players hold a share approximately % in sales volume, and in term of revenue of Haemophilia Treatment, the top five companies hold a share nearly %.
In terms of sales (consumption) side, this report focuses on the sales of Haemophilia Treatment by regions (Countries), company, by type and by type. from 2018 to 2024 and forecast to 2034.
The global Haemophilia Treatment market is thoroughly, accurately, and comprehensively assessed in the report with a large focus on market dynamics, market competition, regional growth, segmental analysis, and key growth strategies. Buyers of the report will have access to verified market figures, including global market size in terms of revenue and volume. As part of sales analysis, the authors of the report have provided reliable estimations and calculations for global revenue and sales by type segment of the global Haemophilia Treatment market. These figures have been provided in terms of both revenue and sales for the period 2018-2034. Additionally, the report provides accurate figures for sales by region in terms of revenue as well as volume for the same period.



By Company


Bayer
Novo Nordisk
Pfizer
Roche
Aptevo Therapeutics
Catalyst BioSciences
Dimension Therapeutics
Takeda
CSL Behring
Alnylam Pharmaceuticals
By Type
Haemophilia A
Haemophilia B
By Application
Hospital
Pharmaceutical Companies
Other
Sales by Region
North America
U.S.
Canada
China
APAC (excluding China)
Japan
South Korea
China Taiwan
Southeast Asia
Europe
Germany
France
U.K.
Italy
Russia
Middle East, Africa, Latin America
Brazil
Mexico
Turkey
Israel
GCC Countries

Chapter Outline


Chapter 1Introduces the report scope of the report, executive summary of different market segments (by type and by application, etc.), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2Sales (consumption), revenue of Haemophilia Treatment in global, regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space of each country in the world.
Chapter 3Detailed analysis of Haemophilia Treatment manufacturers competitive landscape, price, sales, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.
Chapter 4Provides the analysis of various market segments by type, covering the sales, revenue, average price, and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5Provides the analysis of various market segments by application, covering the sales, revenue, average price, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6North America by company, by type, by application and by country, sales, and revenue for each segment.
Chapter 7Europe by company, by type, by application and by country, sales, and revenue for each segment.
Chapter 8China by company, by type and by application, sales, and revenue for each segment.
Chapter 9APAC (excluding China) by company, by type, by application and by region, sales, and revenue for each segment.
Chapter 10Middle East, Africa, and Latin America by company, by type, by application and by country, sales, and revenue for each segment.
Chapter 11Provides profiles of key manufacturers, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Haemophilia Treatment sales, revenue, price, gross margin, and recent development, etc.
Chapter 12Analysis of industrial chain, sales channel, key raw materials, distributors, and customers.
Chapter 13Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 14The main points and conclusions of the report.

Table of Content

1 Report Overview
1.1 Haemophilia Treatment Definition
1.2 Market by Type
1.2.1 Global Haemophilia Treatment Market Size Growth Rate by Type, 2018 VS 2022 VS 2034
1.2.2 Haemophilia A
1.2.3 Haemophilia B
1.3 Market Segment by Application
1.3.1 Global Haemophilia Treatment Market Size Growth Rate by Application, 2018 VS 2022 VS 2034
1.3.2 Hospital
1.3.3 Pharmaceutical Companies
1.3.4 Other
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Global Haemophilia Treatment Sales
2.1 Global Haemophilia Treatment Revenue Estimates and Forecasts 2018-2034
2.2 Global Haemophilia Treatment Revenue by Region: 2018 VS 2022 VS 2034
2.3 Global Haemophilia Treatment Revenue by Region
2.3.1 Global Haemophilia Treatment Revenue by Region (2018-2024)
2.3.2 Global Haemophilia Treatment Revenue by Region (2024-2034)
2.4 Global Haemophilia Treatment Sales Quantity Estimates and Forecasts 2018-2034
2.5 Global Haemophilia Treatment Sales Quantity by Region: 2018 VS 2022 VS 2034
2.6 Global Haemophilia Treatment Sales Quantity by Region
2.6.1 Global Haemophilia Treatment Sales Quantity by Region (2018-2024)
2.6.2 Global Haemophilia Treatment Sales Quantity by Region (2024-2034)
2.7 North America
2.8 Europe
2.9 China
2.10 APAC (excluding China)
2.11 Middle East, Africa and Latin America
3 Competition by Manufacturers
3.1 Global Haemophilia Treatment Sales Quantity by Manufacturers
3.1.1 Global Haemophilia Treatment Sales Quantity by Manufacturers (2018-2024)
3.1.2 Global Haemophilia Treatment Sales Quantity Share by Manufacturers (2018-2024)
3.1.3 Global Top 10 and Top 5 Companies by Haemophilia Treatment Sales in 2022
3.2 Global Haemophilia Treatment Revenue by Manufacturers
3.2.1 Global Haemophilia Treatment Revenue by Manufacturers (2018-2024)
3.2.2 Global Haemophilia Treatment Revenue Share by Manufacturers (2018-2024)
3.2.3 Global Top 10 and Top 5 Companies by Haemophilia Treatment Revenue in 2022
3.3 Global Haemophilia Treatment Sales Price by Manufacturers
3.4 Global Key Players of Haemophilia Treatment, Industry Ranking, 2021 VS 2022
3.5 Analysis of Competitive Landscape
3.5.1 Manufacturers Market Concentration Ratio (CR5 and HHI)
3.5.2 Global Haemophilia Treatment Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.6 Global Key Manufacturers of Haemophilia Treatment, Manufacturing Base Distribution and Headquarters
3.7 Global Key Manufacturers of Haemophilia Treatment, Product Offered and Application
3.8 Global Key Manufacturers of Haemophilia Treatment, Date of Enter into This Industry
3.9 Mergers & Acquisitions, Expansion Plans
4 Estimates and Forecasts by Type
4.1 Global Haemophilia Treatment Sales Quantity by Type
4.1.1 Global Haemophilia Treatment Historical Sales Quantity by Type (2018-2024)
4.1.2 Global Haemophilia Treatment Forecasted Sales Quantity by Type (2024-2034)
4.1.3 Global Haemophilia Treatment Sales Quantity Market Share by Type (2018-2034)
4.2 Global Haemophilia Treatment Revenue by Type
4.2.1 Global Haemophilia Treatment Historical Revenue by Type (2018-2024)
4.2.2 Global Haemophilia Treatment Forecasted Revenue by Type (2024-2034)
4.2.3 Global Haemophilia Treatment Revenue Market Share by Type (2018-2034)
4.3 Global Haemophilia Treatment Price by Type
4.3.1 Global Haemophilia Treatment Price by Type (2018-2024)
4.3.2 Global Haemophilia Treatment Price Forecast by Type (2024-2034)
5 Market Size by Application
5.1 Global Haemophilia Treatment Sales Quantity by Application
5.1.1 Global Haemophilia Treatment Historical Sales Quantity by Application (2018-2024)
5.1.2 Global Haemophilia Treatment Forecasted Sales Quantity by Application (2024-2034)
5.1.3 Global Haemophilia Treatment Sales Quantity Market Share by Application (2018-2034)
5.2 Global Haemophilia Treatment Revenue by Application
5.2.1 Global Haemophilia Treatment Historical Revenue by Application (2018-2024)
5.2.2 Global Haemophilia Treatment Forecasted Revenue by Application (2024-2034)
5.2.3 Global Haemophilia Treatment Revenue Market Share by Application (2018-2034)
5.3 Global Haemophilia Treatment Price by Application
5.3.1 Global Haemophilia Treatment Price by Application (2018-2024)
5.3.2 Global Haemophilia Treatment Price Forecast by Application (2024-2034)
6 North America
6.1 North America Haemophilia Treatment Sales by Company
6.1.1 North America Haemophilia Treatment Revenue by Company (2018-2024)
6.1.2 North America Haemophilia Treatment Sales Quantity by Company (2018-2024)
6.2 North America Haemophilia Treatment Market Size by Type
6.2.1 North America Haemophilia Treatment Sales Quantity by Type (2018-2034)
6.2.2 North America Haemophilia Treatment Revenue by Type (2018-2034)
6.3 North America Haemophilia Treatment Market Size by Application
6.3.1 North America Haemophilia Treatment Sales Quantity by Application (2018-2034)
6.3.2 North America Haemophilia Treatment Revenue by Application (2018-2034)
6.4 North America Haemophilia Treatment Market Size by Country
6.4.1 North America Haemophilia Treatment Revenue by Country: 2018 VS 2022 VS 2034
6.4.2 North America Haemophilia Treatment Revenue by Country (2018-2034)
6.4.3 North America Haemophilia Treatment Sales Quantity by Country (2018-2034)
6.4.4 U.S.
6.4.5 Canada
7 Europe
7.1 Europe Haemophilia Treatment Sales by Company
7.1.1 Europe Haemophilia Treatment Sales Quantity by Company (2018-2024)
7.1.2 Europe Haemophilia Treatment Revenue by Company (2018-2024)
7.2 Europe Haemophilia Treatment Market Size by Type
7.2.1 Europe Haemophilia Treatment Sales Quantity by Type (2018-2034)
7.2.2 Europe Haemophilia Treatment Revenue by Type (2018-2034)
7.3 Europe Haemophilia Treatment Market Size by Application
7.3.1 Europe Haemophilia Treatment Sales Quantity by Application (2018-2034)
7.3.2 Europe Haemophilia Treatment Revenue by Application (2018-2034)
7.4 Europe Haemophilia Treatment Market Size by Country
7.4.1 Europe Haemophilia Treatment Revenue by Country: 2018 VS 2022 VS 2034
7.4.2 Europe Haemophilia Treatment Revenue by Country (2018-2034)
7.4.3 Europe Haemophilia Treatment Sales Quantity by Country (2018-2034)
7.4.4 Germany
7.4.5 France
7.4.6 U.K.
7.4.7 Italy
7.4.8 Russia
8 China
8.1 China Haemophilia Treatment Sales by Company
8.1.1 China Haemophilia Treatment Sales Quantity by Company (2018-2024)
8.1.2 China Haemophilia Treatment Revenue by Company (2018-2024)
8.2 China Haemophilia Treatment Market Size by Type
8.2.1 China Haemophilia Treatment Sales Quantity by Type (2018-2034)
8.2.2 China Haemophilia Treatment Revenue by Type (2018-2034)
8.3 China Haemophilia Treatment Market Size by Application
8.3.1 China Haemophilia Treatment Sales Quantity by Application (2018-2034)
8.3.2 China Haemophilia Treatment Revenue by Application (2018-2034)
9 APAC (excluding China)
9.1 APAC Haemophilia Treatment Sales by Company
9.1.1 APAC Haemophilia Treatment Sales Quantity by Company (2018-2024)
9.1.2 APAC Haemophilia Treatment Revenue by Company (2018-2024)
9.2 APAC Haemophilia Treatment Market Size by Type
9.2.1 APAC Haemophilia Treatment Sales Quantity by Type (2018-2034)
9.2.2 APAC Haemophilia Treatment Revenue by Type (2018-2034)
9.3 APAC Haemophilia Treatment Market Size by Application
9.3.1 APAC Haemophilia Treatment Sales Quantity by Application (2018-2034)
9.3.2 APAC Haemophilia Treatment Revenue by Application (2018-2034)
9.4 APAC Haemophilia Treatment Market Size by Region
9.4.1 APAC Haemophilia Treatment Revenue by Region: 2018 VS 2022 VS 2034
9.4.2 APAC Haemophilia Treatment Revenue by Region (2018-2034)
9.4.3 APAC Haemophilia Treatment Sales Quantity by Region (2018-2034)
9.4.4 Japan
9.4.5 South Korea
9.4.6 China Taiwan
9.4.7 Southeast Asia
9.4.8 India
10 Middle East, Africa and Latin America
10.1 Middle East, Africa and Latin America Haemophilia Treatment Sales by Company
10.1.1 Middle East, Africa and Latin America Haemophilia Treatment Sales Quantity by Company (2018-2024)
10.1.2 Middle East, Africa and Latin America Haemophilia Treatment Revenue by Company (2018-2024)
10.2 Middle East, Africa and Latin America Haemophilia Treatment Market Size by Type
10.2.1 Middle East, Africa and Latin America Haemophilia Treatment Sales Quantity by Type (2018-2034)
10.2.2 Middle East, Africa and Latin America Haemophilia Treatment Revenue by Type (2018-2034)
10.3 Middle East, Africa and Latin America Haemophilia Treatment Market Size by Application
10.3.1 Middle East, Africa and Latin America Haemophilia Treatment Sales Quantity by Application (2018-2034)
10.3.2 Middle East, Africa and Latin America Haemophilia Treatment Revenue by Application (2018-2034)
10.4 Middle East, Africa and Latin America Haemophilia Treatment Market Size by Country
10.4.1 Middle East, Africa and Latin America Haemophilia Treatment Revenue by Country: 2018 VS 2022 VS 2034
10.4.2 Middle East, Africa and Latin America Haemophilia Treatment Revenue by Country (2018-2034)
10.4.3 Middle East, Africa and Latin America Haemophilia Treatment Sales Quantity by Country (2018-2034)
10.4.4 Brazil
10.4.5 Mexico
10.4.6 Turkey
10.4.7 Israel
10.4.8 GCC Countries
11 Company Profiles
11.1 Bayer
11.1.1 Bayer Company Information
11.1.2 Bayer Overview
11.1.3 Bayer Haemophilia Treatment Sales Quantity, Revenue, Average Selling Price (ASP) and Gross Margin (2018-2024)
11.1.4 Bayer Haemophilia Treatment Products and Services
11.1.5 Bayer Haemophilia Treatment SWOT Analysis
11.1.6 Bayer Recent Developments
11.2 Novo Nordisk
11.2.1 Novo Nordisk Company Information
11.2.2 Novo Nordisk Overview
11.2.3 Novo Nordisk Haemophilia Treatment Sales Quantity, Revenue, Average Selling Price (ASP) and Gross Margin (2018-2024)
11.2.4 Novo Nordisk Haemophilia Treatment Products and Services
11.2.5 Novo Nordisk Haemophilia Treatment SWOT Analysis
11.2.6 Novo Nordisk Recent Developments
11.3 Pfizer
11.3.1 Pfizer Company Information
11.3.2 Pfizer Overview
11.3.3 Pfizer Haemophilia Treatment Sales Quantity, Revenue, Average Selling Price (ASP) and Gross Margin (2018-2024)
11.3.4 Pfizer Haemophilia Treatment Products and Services
11.3.5 Pfizer Haemophilia Treatment SWOT Analysis
11.3.6 Pfizer Recent Developments
11.4 Roche
11.4.1 Roche Company Information
11.4.2 Roche Overview
11.4.3 Roche Haemophilia Treatment Sales Quantity, Revenue, Average Selling Price (ASP) and Gross Margin (2018-2024)
11.4.4 Roche Haemophilia Treatment Products and Services
11.4.5 Roche Haemophilia Treatment SWOT Analysis
11.4.6 Roche Recent Developments
11.5 Aptevo Therapeutics
11.5.1 Aptevo Therapeutics Company Information
11.5.2 Aptevo Therapeutics Overview
11.5.3 Aptevo Therapeutics Haemophilia Treatment Sales Quantity, Revenue, Average Selling Price (ASP) and Gross Margin (2018-2024)
11.5.4 Aptevo Therapeutics Haemophilia Treatment Products and Services
11.5.5 Aptevo Therapeutics Haemophilia Treatment SWOT Analysis
11.5.6 Aptevo Therapeutics Recent Developments
11.6 Catalyst BioSciences
11.6.1 Catalyst BioSciences Company Information
11.6.2 Catalyst BioSciences Overview
11.6.3 Catalyst BioSciences Haemophilia Treatment Sales Quantity, Revenue, Average Selling Price (ASP) and Gross Margin (2018-2024)
11.6.4 Catalyst BioSciences Haemophilia Treatment Products and Services
11.6.5 Catalyst BioSciences Haemophilia Treatment SWOT Analysis
11.6.6 Catalyst BioSciences Recent Developments
11.7 Dimension Therapeutics
11.7.1 Dimension Therapeutics Company Information
11.7.2 Dimension Therapeutics Overview
11.7.3 Dimension Therapeutics Haemophilia Treatment Sales Quantity, Revenue, Average Selling Price (ASP) and Gross Margin (2018-2024)
11.7.4 Dimension Therapeutics Haemophilia Treatment Products and Services
11.7.5 Dimension Therapeutics Haemophilia Treatment SWOT Analysis
11.7.6 Dimension Therapeutics Recent Developments
11.8 Takeda
11.8.1 Takeda Company Information
11.8.2 Takeda Overview
11.8.3 Takeda Haemophilia Treatment Sales Quantity, Revenue, Average Selling Price (ASP) and Gross Margin (2018-2024)
11.8.4 Takeda Haemophilia Treatment Products and Services
11.8.5 Takeda Haemophilia Treatment SWOT Analysis
11.8.6 Takeda Recent Developments
11.9 CSL Behring
11.9.1 CSL Behring Company Information
11.9.2 CSL Behring Overview
11.9.3 CSL Behring Haemophilia Treatment Sales Quantity, Revenue, Average Selling Price (ASP) and Gross Margin (2018-2024)
11.9.4 CSL Behring Haemophilia Treatment Products and Services
11.9.5 CSL Behring Haemophilia Treatment SWOT Analysis
11.9.6 CSL Behring Recent Developments
11.10 Alnylam Pharmaceuticals
11.10.1 Alnylam Pharmaceuticals Company Information
11.10.2 Alnylam Pharmaceuticals Overview
11.10.3 Alnylam Pharmaceuticals Haemophilia Treatment Sales Quantity, Revenue, Average Selling Price (ASP) and Gross Margin (2018-2024)
11.10.4 Alnylam Pharmaceuticals Haemophilia Treatment Products and Services
11.10.5 Alnylam Pharmaceuticals Haemophilia Treatment SWOT Analysis
11.10.6 Alnylam Pharmaceuticals Recent Developments
12 Value Chain and Sales Channels Analysis
12.1 Haemophilia Treatment Value Chain Analysis
12.2 Haemophilia Treatment Key Raw Materials
12.2.1 Key Raw Materials
12.2.2 Raw Materials Key Suppliers
12.3 Haemophilia Treatment Production Mode & Process
12.4 Haemophilia Treatment Sales and Marketing
12.4.1 Haemophilia Treatment Sales Channels
12.4.2 Haemophilia Treatment Distributors
12.5 Haemophilia Treatment Customers
13 Market Dynamics
13.1 Haemophilia Treatment Industry Trends
13.2 Haemophilia Treatment Market Drivers
13.3 Haemophilia Treatment Market Challenges
13.4 Haemophilia Treatment Market Restraints
14 Key Findings
15 Appendix
15.1 Research Methodology
15.1.1 Methodology/Research Approach
15.1.2 Data Source
15.2 Author Details
15.3 Disclaimer

List of Figure

List of Tables
Table 1. Global Haemophilia Treatment Market Size Growth Rate (CAGR) by Type, 2018 VS 2022 VS 2034 (US$ Million)
Table 2. Major Manufacturers of Haemophilia A
Table 3. Major Manufacturers of Haemophilia B
Table 4. Global Haemophilia Treatment Market Size Growth Rate (CAGR) by Application, 2018 VS 2022 VS 2034 (US$ Million)
Table 5. Global Haemophilia Treatment Revenue by Region: 2018 VS 2022 VS 2034 (US$ Million)
Table 6. Global Haemophilia Treatment Revenue by Region (2018-2024) & (US$ Million)
Table 7. Global Haemophilia Treatment Revenue Market Share by Region (2018-2024)
Table 8. Global Haemophilia Treatment Revenue by Region (2024-2034) & (US$ Million)
Table 9. Global Haemophilia Treatment Revenue Market Share by Region (2024-2034)
Table 10. Global Haemophilia Treatment Sales Quantity by Region: 2018 VS 2022 VS 2034 (K Units)
Table 11. Global Haemophilia Treatment Sales by Region (2018-2024) & (K Units)
Table 12. Global Haemophilia Treatment Sales Market Share by Region (2018-2024)
Table 13. Global Haemophilia Treatment Sales by Region (2024-2034) & (K Units)
Table 14. Global Haemophilia Treatment Sales Market Share by Region (2024-2034)
Table 15. Global Haemophilia Treatment Sales Quantity by Manufacturers (2018-2024) & (K Units)
Table 16. Global Haemophilia Treatment Sales Quantity Share by Manufacturers (2018-2024)
Table 17. Global Haemophilia Treatment Revenue by Manufacturers (2018-2024) & (US$ Million)
Table 18. Global Haemophilia Treatment Revenue Share by Manufacturers (2018-2024)
Table 19. Global Haemophilia Treatment Price by Manufacturers 2018-2024 (USD/Unit)
Table 20. Global Key Players of Haemophilia Treatment, Industry Ranking, 2021 VS 2022
Table 21. Global Haemophilia Treatment Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 22. Global Haemophilia Treatment by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Haemophilia Treatment as of 2022)
Table 23. Global Key Manufacturers of Haemophilia Treatment, Manufacturing Base Distribution and Headquarters
Table 24. Global Key Manufacturers of Haemophilia Treatment, Product Offered and Application
Table 25. Global Key Manufacturers of Haemophilia Treatment, Date of Enter into This Industry
Table 26. Mergers & Acquisitions, Expansion Plans
Table 27. Global Haemophilia Treatment Sales Quantity by Type (2018-2024) & (K Units)
Table 28. Global Haemophilia Treatment Sales Quantity by Type (2024-2034) & (K Units)
Table 29. Global Haemophilia Treatment Sales Quantity Share by Type (2018-2024)
Table 30. Global Haemophilia Treatment Sales Quantity Share by Type (2024-2034)
Table 31. Global Haemophilia Treatment Revenue by Type (2018-2024) & (US$ Million)
Table 32. Global Haemophilia Treatment Revenue by Type (2024-2034) & (US$ Million)
Table 33. Global Haemophilia Treatment Revenue Share by Type (2018-2024)
Table 34. Global Haemophilia Treatment Revenue Share by Type (2024-2034)
Table 35. Haemophilia Treatment Price by Type (2018-2024) & (USD/Unit)
Table 36. Global Haemophilia Treatment Price Forecast by Type (2024-2034) & (USD/Unit)
Table 37. Global Haemophilia Treatment Sales Quantity by Application (2018-2024) & (K Units)
Table 38. Global Haemophilia Treatment Sales Quantity by Application (2024-2034) & (K Units)
Table 39. Global Haemophilia Treatment Sales Quantity Share by Application (2018-2024)
Table 40. Global Haemophilia Treatment Sales Quantity Share by Application (2024-2034)
Table 41. Global Haemophilia Treatment Revenue by Application (2018-2024) & (US$ Million)
Table 42. Global Haemophilia Treatment Revenue by Application (2024-2034) & (US$ Million)
Table 43. Global Haemophilia Treatment Revenue Share by Application (2018-2024)
Table 44. Global Haemophilia Treatment Revenue Share by Application (2024-2034)
Table 45. Haemophilia Treatment Price by Application (2018-2024) & (USD/Unit)
Table 46. Global Haemophilia Treatment Price Forecast by Application (2024-2034) & (USD/Unit)
Table 47. North America Haemophilia Treatment Revenue by Company (2018-2024) & (US$ Million)
Table 48. North America Haemophilia Treatment Sales Quantity by Company (2018-2024) & (K Units)
Table 49. North America Haemophilia Treatment Sales Quantity by Type (2018-2024) & (K Units)
Table 50. North America Haemophilia Treatment Sales Quantity by Type (2024-2034) & (K Units)
Table 51. North America Haemophilia Treatment Revenue by Type (2018-2024) & (US$ Million)
Table 52. North America Haemophilia Treatment Revenue by Type (2024-2034) & (US$ Million)
Table 53. North America Haemophilia Treatment Sales Quantity by Application (2018-2024) & (K Units)
Table 54. North America Haemophilia Treatment Sales Quantity by Application (2024-2034) & (K Units)
Table 55. North America Haemophilia Treatment Revenue by Application (2018-2024) & (US$ Million)
Table 56. North America Haemophilia Treatment Revenue by Application (2024-2034) & (US$ Million)
Table 57. North America Haemophilia Treatment Revenue by Country: 2018 VS 2022 VS 2034 (US$ Million)
Table 58. North America Haemophilia Treatment Revenue by Country (2018-2024) & (US$ Million)
Table 59. North America Haemophilia Treatment Revenue by Country (2024-2034) & (US$ Million)
Table 60. North America Haemophilia Treatment Sales Quantity by Country (2018-2024) & (K Units)
Table 61. North America Haemophilia Treatment Sales Quantity by Country (2024-2034) & (K Units)
Table 62. Europe Haemophilia Treatment Sales Quantity by Company (2018-2024) & (K Units)
Table 63. Europe Haemophilia Treatment Revenue by Company (2018-2024) & (US$ Million)
Table 64. Europe Haemophilia Treatment Sales Quantity by Type (2018-2024) & (K Units)
Table 65. Europe Haemophilia Treatment Sales Quantity by Type (2024-2034) & (K Units)
Table 66. Europe Haemophilia Treatment Revenue by Type (2018-2024) & (US$ Million)
Table 67. Europe Haemophilia Treatment Revenue by Type (2024-2034) & (US$ Million)
Table 68. Europe Haemophilia Treatment Sales Quantity by Application (2018-2024) & (K Units)
Table 69. Europe Haemophilia Treatment Sales Quantity by Application (2024-2034) & (K Units)
Table 70. Europe Haemophilia Treatment Revenue by Application (2018-2024) & (US$ Million)
Table 71. Europe Haemophilia Treatment Revenue by Application (2024-2034) & (US$ Million)
Table 72. Europe Haemophilia Treatment Revenue by Country: 2018 VS 2022 VS 2034 (US$ Million)
Table 73. Europe Haemophilia Treatment Revenue by Country (2018-2024) & (US$ Million)
Table 74. Europe Haemophilia Treatment Revenue by Country (2024-2034) & (US$ Million)
Table 75. Europe Haemophilia Treatment Sales Quantity by Country (2018-2024) & (K Units)
Table 76. Europe Haemophilia Treatment Sales Quantity by Country (2024-2034) & (K Units)
Table 77. China Haemophilia Treatment Sales Quantity by Company (2018-2024) & (K Units)
Table 78. China Haemophilia Treatment Revenue by Company (2018-2024) & (US$ Million)
Table 79. China Haemophilia Treatment Sales Quantity by Type (2018-2024) & (K Units)
Table 80. China Haemophilia Treatment Sales Quantity by Type (2024-2034) & (K Units)
Table 81. China Haemophilia Treatment Revenue by Type (2018-2024) & (US$ Million)
Table 82. China Haemophilia Treatment Revenue by Type (2024-2034) & (US$ Million)
Table 83. China Haemophilia Treatment Sales Quantity by Application (2018-2024) & (K Units)
Table 84. China Haemophilia Treatment Sales Quantity by Application (2024-2034) & (K Units)
Table 85. China Haemophilia Treatment Revenue by Application (2018-2024) & (US$ Million)
Table 86. China Haemophilia Treatment Revenue by Application (2024-2034) & (US$ Million)
Table 87. APAC Haemophilia Treatment Sales Quantity by Company (2018-2024) & (K Units)
Table 88. APAC Haemophilia Treatment Revenue by Company (2018-2024) & (US$ Million)
Table 89. APAC Haemophilia Treatment Sales Quantity by Type (2018-2024) & (K Units)
Table 90. APAC Haemophilia Treatment Sales Quantity by Type (2024-2034) & (K Units)
Table 91. APAC Haemophilia Treatment Revenue by Type (2018-2024) & (US$ Million)
Table 92. APAC Haemophilia Treatment Revenue by Type (2024-2034) & (US$ Million)
Table 93. APAC Haemophilia Treatment Sales Quantity by Application (2018-2024) & (K Units)
Table 94. APAC Haemophilia Treatment Sales Quantity by Application (2024-2034) & (K Units)
Table 95. APAC Haemophilia Treatment Revenue by Application (2018-2024) & (US$ Million)
Table 96. APAC Haemophilia Treatment Revenue by Application (2024-2034) & (US$ Million)
Table 97. APAC Haemophilia Treatment Revenue by Region: 2018 VS 2022 VS 2034 (US$ Million)
Table 98. APAC Haemophilia Treatment Revenue by Region (2018-2024) & (US$ Million)
Table 99. APAC Haemophilia Treatment Revenue by Region (2024-2034) & (US$ Million)
Table 100. APAC Haemophilia Treatment Sales Quantity by Region (2018-2024) & (K Units)
Table 101. APAC Haemophilia Treatment Sales Quantity by Region (2024-2034) & (K Units)
Table 102. Middle East, Africa and Latin America Haemophilia Treatment Sales Quantity by Company (2018-2024) & (K Units)
Table 103. Middle East, Africa and Latin America Haemophilia Treatment Revenue by Company (2018-2024) & (US$ Million)
Table 104. Middle East, Africa and Latin America Haemophilia Treatment Sales Quantity by Type (2018-2024) & (K Units)
Table 105. Middle East, Africa and Latin America Haemophilia Treatment Sales Quantity by Type (2024-2034) & (K Units)
Table 106. Middle East, Africa and Latin America Haemophilia Treatment Revenue by Type (2018-2024) & (US$ Million)
Table 107. Middle East, Africa and Latin America Haemophilia Treatment Revenue by Type (2024-2034) & (US$ Million)
Table 108. Middle East, Africa and Latin America Haemophilia Treatment Sales Quantity by Application (2018-2024) & (K Units)
Table 109. Middle East, Africa and Latin America Haemophilia Treatment Sales Quantity by Application (2024-2034) & (K Units)
Table 110. Middle East, Africa and Latin America Haemophilia Treatment Revenue by Application (2018-2024) & (US$ Million)
Table 111. Middle East, Africa and Latin America Haemophilia Treatment Revenue by Application (2024-2034) & (US$ Million)
Table 112. Middle East, Africa and Latin America Haemophilia Treatment Revenue by Country: 2018 VS 2022 VS 2034 (US$ Million)
Table 113. Middle East, Africa and Latin America Haemophilia Treatment Revenue by Country (2018-2024) & (US$ Million)
Table 114. Middle East, Africa and Latin America Haemophilia Treatment Revenue by Country (2024-2034) & (US$ Million)
Table 115. Middle East, Africa and Latin America Haemophilia Treatment Sales Quantity by Country (2018-2024) & (K Units)
Table 116. Middle East, Africa and Latin America Haemophilia Treatment Sales Quantity by Country (2024-2034) & (K Units)
Table 117. Bayer Company Information
Table 118. Bayer Description and Overview
Table 119. Bayer Haemophilia Treatment Sales Quantity (K Units), Revenue (US$ Million), Average Selling Price (ASP) (USD/Unit) and Gross Margin (2018-2024)
Table 120. Bayer Haemophilia Treatment Product and Services
Table 121. Bayer Haemophilia Treatment SWOT Analysis
Table 122. Bayer Recent Developments
Table 123. Novo Nordisk Company Information
Table 124. Novo Nordisk Description and Overview
Table 125. Novo Nordisk Haemophilia Treatment Sales Quantity (K Units), Revenue (US$ Million), Average Selling Price (ASP) (USD/Unit) and Gross Margin (2018-2024)
Table 126. Novo Nordisk Haemophilia Treatment Product and Services
Table 127. Novo Nordisk Haemophilia Treatment SWOT Analysis
Table 128. Novo Nordisk Recent Developments
Table 129. Pfizer Company Information
Table 130. Pfizer Description and Overview
Table 131. Pfizer Haemophilia Treatment Sales Quantity (K Units), Revenue (US$ Million), Average Selling Price (ASP) (USD/Unit) and Gross Margin (2018-2024)
Table 132. Pfizer Haemophilia Treatment Product and Services
Table 133. Pfizer Haemophilia Treatment SWOT Analysis
Table 134. Pfizer Recent Developments
Table 135. Roche Company Information
Table 136. Roche Description and Overview
Table 137. Roche Haemophilia Treatment Sales Quantity (K Units), Revenue (US$ Million), Average Selling Price (ASP) (USD/Unit) and Gross Margin (2018-2024)
Table 138. Roche Haemophilia Treatment Product and Services
Table 139. Roche Haemophilia Treatment SWOT Analysis
Table 140. Roche Recent Developments
Table 141. Aptevo Therapeutics Company Information
Table 142. Aptevo Therapeutics Description and Overview
Table 143. Aptevo Therapeutics Haemophilia Treatment Sales Quantity (K Units), Revenue (US$ Million), Average Selling Price (ASP) (USD/Unit) and Gross Margin (2018-2024)
Table 144. Aptevo Therapeutics Haemophilia Treatment Product and Services
Table 145. Aptevo Therapeutics Haemophilia Treatment SWOT Analysis
Table 146. Aptevo Therapeutics Recent Developments
Table 147. Catalyst BioSciences Company Information
Table 148. Catalyst BioSciences Description and Overview
Table 149. Catalyst BioSciences Haemophilia Treatment Sales Quantity (K Units), Revenue (US$ Million), Average Selling Price (ASP) (USD/Unit) and Gross Margin (2018-2024)
Table 150. Catalyst BioSciences Haemophilia Treatment Product and Services
Table 151. Catalyst BioSciences Haemophilia Treatment SWOT Analysis
Table 152. Catalyst BioSciences Recent Developments
Table 153. Dimension Therapeutics Company Information
Table 154. Dimension Therapeutics Description and Overview
Table 155. Dimension Therapeutics Haemophilia Treatment Sales Quantity (K Units), Revenue (US$ Million), Average Selling Price (ASP) (USD/Unit) and Gross Margin (2018-2024)
Table 156. Dimension Therapeutics Haemophilia Treatment Product and Services
Table 157. Dimension Therapeutics Haemophilia Treatment SWOT Analysis
Table 158. Dimension Therapeutics Recent Developments
Table 159. Takeda Company Information
Table 160. Takeda Description and Overview
Table 161. Takeda Haemophilia Treatment Sales Quantity (K Units), Revenue (US$ Million), Average Selling Price (ASP) (USD/Unit) and Gross Margin (2018-2024)
Table 162. Takeda Haemophilia Treatment Product and Services
Table 163. Takeda Haemophilia Treatment SWOT Analysis
Table 164. Takeda Recent Developments
Table 165. CSL Behring Company Information
Table 166. CSL Behring Description and Overview
Table 167. CSL Behring Haemophilia Treatment Sales Quantity (K Units), Revenue (US$ Million), Average Selling Price (ASP) (USD/Unit) and Gross Margin (2018-2024)
Table 168. CSL Behring Haemophilia Treatment Product and Services
Table 169. CSL Behring Haemophilia Treatment SWOT Analysis
Table 170. CSL Behring Recent Developments
Table 171. Alnylam Pharmaceuticals Company Information
Table 172. Alnylam Pharmaceuticals Description and Overview
Table 173. Alnylam Pharmaceuticals Haemophilia Treatment Sales Quantity (K Units), Revenue (US$ Million), Average Selling Price (ASP) (USD/Unit) and Gross Margin (2018-2024)
Table 174. Alnylam Pharmaceuticals Haemophilia Treatment Product and Services
Table 175. Alnylam Pharmaceuticals Haemophilia Treatment SWOT Analysis
Table 176. Alnylam Pharmaceuticals Recent Developments
Table 177. Key Raw Materials Lists
Table 178. Raw Materials Key Suppliers Lists
Table 179. Haemophilia Treatment Distributors List
Table 180. Haemophilia Treatment Customers List
Table 181. Haemophilia Treatment Market Trends
Table 182. Haemophilia Treatment Market Drivers
Table 183. Haemophilia Treatment Market Challenges
Table 184. Haemophilia Treatment Market Restraints
Table 185. Research Programs/Design for This Report
Table 186. Key Data Information from Secondary Sources
Table 187. Key Data Information from Primary Sources
List of Figures
Figure 1. Haemophilia Treatment Product Picture
Figure 2. Global Haemophilia Treatment Market Size Growth Rate by Type, 2018 VS 2022 VS 2034 (US$ Million)
Figure 3. Global Haemophilia Treatment Market Share by Type in 2022 & 2034
Figure 4. Haemophilia A Product Picture
Figure 5. Haemophilia B Product Picture
Figure 6. Global Haemophilia Treatment Market Size Growth Rate by Application, 2018 VS 2022 VS 2034 (US$ Million)
Figure 7. Global Haemophilia Treatment Market Share by Application in 2022 & 2034
Figure 8. Hospital
Figure 9. Pharmaceutical Companies
Figure 10. Other
Figure 11. Haemophilia Treatment Report Years Considered
Figure 12. Global Haemophilia Treatment Revenue, (US$ Million), 2018 VS 2022 VS 2034
Figure 13. Global Haemophilia Treatment Revenue 2018-2034 (US$ Million)
Figure 14. Global Haemophilia Treatment Revenue Market Share by Region in Percentage: 2022 Versus 2034
Figure 15. Global Haemophilia Treatment Sales Quantity 2018-2034 (K Units)
Figure 16. Global Haemophilia Treatment Sales Quantity Market Share by Region (2018-2024)
Figure 17. Global Haemophilia Treatment Sales Quantity Market Share by Region (2024-2034)
Figure 18. North America Haemophilia Treatment Sales Quantity YoY (2018-2034) & (K Units)
Figure 19. North America Haemophilia Treatment Revenue YoY (2018-2034) & (US$ Million)
Figure 20. Europe Haemophilia Treatment Sales Quantity YoY (2018-2034) & (K Units)
Figure 21. Europe Haemophilia Treatment Revenue YoY (2018-2034) & (US$ Million)
Figure 22. China Haemophilia Treatment Sales Quantity YoY (2018-2034) & (K Units)
Figure 23. China Haemophilia Treatment Revenue YoY (2018-2034) & (US$ Million)
Figure 24. APAC Haemophilia Treatment Sales Quantity YoY (2018-2034) & (K Units)
Figure 25. APAC Haemophilia Treatment Revenue YoY (2018-2034) & (US$ Million)
Figure 26. Middle East, Africa and Latin America Haemophilia Treatment Sales Quantity YoY (2018-2034) & (K Units)
Figure 27. Middle East, Africa and Latin America Haemophilia Treatment Revenue YoY (2018-2034) & (US$ Million)
Figure 28. The Top 10 and Top 5 Players Market Share by Haemophilia Treatment Sales Quantity in 2022
Figure 29. The Top 10 and Top 5 Players Market Share by Haemophilia Treatment Revenue in 2022
Figure 30. Haemophilia Treatment Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2018 VS 2022
Figure 31. Global Haemophilia Treatment Sales Quantity Market Share by Type (2018-2034)
Figure 32. Global Haemophilia Treatment Revenue Market Share by Type (2018-2034)
Figure 33. Global Haemophilia Treatment Sales Quantity Market Share by Application (2018-2034)
Figure 34. Global Haemophilia Treatment Revenue Market Share by Application (2018-2034)
Figure 35. North America Haemophilia Treatment Revenue Market Share by Company in 2022
Figure 36. North America Haemophilia Treatment Sales Quantity Market Share by Company in 2022
Figure 37. North America Haemophilia Treatment Sales Quantity Market Share by Type (2018-2034)
Figure 38. North America Haemophilia Treatment Revenue Market Share by Type (2018-2034)
Figure 39. North America Haemophilia Treatment Sales Quantity Market Share by Application (2018-2034)
Figure 40. North America Haemophilia Treatment Revenue Market Share by Application (2018-2034)
Figure 41. North America Haemophilia Treatment Revenue Share by Country (2018-2034)
Figure 42. North America Haemophilia Treatment Sales Quantity Share by Country (2018-2034)
Figure 43. U.S. Haemophilia Treatment Revenue (2018-2034) & (US$ Million)
Figure 44. Canada Haemophilia Treatment Revenue (2018-2034) & (US$ Million)
Figure 45. Europe Haemophilia Treatment Sales Quantity Market Share by Company in 2022
Figure 46. Europe Haemophilia Treatment Revenue Market Share by Company in 2022
Figure 47. Europe Haemophilia Treatment Sales Quantity Market Share by Type (2018-2034)
Figure 48. Europe Haemophilia Treatment Revenue Market Share by Type (2018-2034)
Figure 49. Europe Haemophilia Treatment Sales Quantity Market Share by Application (2018-2034)
Figure 50. Europe Haemophilia Treatment Revenue Market Share by Application (2018-2034)
Figure 51. Europe Haemophilia Treatment Revenue Share by Country (2018-2034)
Figure 52. Europe Haemophilia Treatment Sales Quantity Share by Country (2018-2034)
Figure 53. Germany Haemophilia Treatment Revenue (2018-2034) & (US$ Million)
Figure 54. France Haemophilia Treatment Revenue (2018-2034) & (US$ Million)
Figure 55. U.K. Haemophilia Treatment Revenue (2018-2034) & (US$ Million)
Figure 56. Italy Haemophilia Treatment Revenue (2018-2034) & (US$ Million)
Figure 57. Russia Haemophilia Treatment Revenue (2018-2034) & (US$ Million)
Figure 58. China Haemophilia Treatment Sales Quantity Market Share by Company in 2022
Figure 59. China Haemophilia Treatment Revenue Market Share by Company in 2022
Figure 60. China Haemophilia Treatment Sales Quantity Market Share by Type (2018-2034)
Figure 61. China Haemophilia Treatment Revenue Market Share by Type (2018-2034)
Figure 62. China Haemophilia Treatment Sales Quantity Market Share by Application (2018-2034)
Figure 63. China Haemophilia Treatment Revenue Market Share by Application (2018-2034)
Figure 64. APAC Haemophilia Treatment Sales Quantity Market Share by Company in 2022
Figure 65. APAC Haemophilia Treatment Revenue Market Share by Company in 2022
Figure 66. APAC Haemophilia Treatment Sales Quantity Market Share by Type (2018-2034)
Figure 67. APAC Haemophilia Treatment Revenue Market Share by Type (2018-2034)
Figure 68. APAC Haemophilia Treatment Sales Quantity Market Share by Application (2018-2034)
Figure 69. APAC Haemophilia Treatment Revenue Market Share by Application (2018-2034)
Figure 70. APAC Haemophilia Treatment Revenue Share by Region (2018-2034)
Figure 71. APAC Haemophilia Treatment Sales Quantity Share by Region (2018-2034)
Figure 72. Japan Haemophilia Treatment Revenue (2018-2034) & (US$ Million)
Figure 73. South Korea Haemophilia Treatment Revenue (2018-2034) & (US$ Million)
Figure 74. China Taiwan Haemophilia Treatment Revenue (2018-2034) & (US$ Million)
Figure 75. Southeast Asia Haemophilia Treatment Revenue (2018-2034) & (US$ Million)
Figure 76. India Haemophilia Treatment Revenue (2018-2034) & (US$ Million)
Figure 77. Middle East, Africa and Latin America Haemophilia Treatment Sales Quantity Market Share by Company in 2022
Figure 78. Middle East, Africa and Latin America Haemophilia Treatment Revenue Market Share by Company in 2022
Figure 79. Middle East, Africa and Latin America Haemophilia Treatment Sales Quantity Market Share by Type (2018-2034)
Figure 80. Middle East, Africa and Latin America Haemophilia Treatment Revenue Market Share by Type (2018-2034)
Figure 81. Middle East, Africa and Latin America Haemophilia Treatment Sales Quantity Market Share by Application (2018-2034)
Figure 82. Middle East, Africa and Latin America Haemophilia Treatment Revenue Market Share by Application (2018-2034)
Figure 83. Middle East, Africa and Latin America Haemophilia Treatment Sales Quantity Share by Country (2018-2034)
Figure 84. Middle East, Africa and Latin America Haemophilia Treatment Revenue Share by Country (2018-2034)
Figure 85. Brazil Haemophilia Treatment Revenue (2018-2034) & (US$ Million)
Figure 86. Mexico Haemophilia Treatment Revenue (2018-2034) & (US$ Million)
Figure 87. Turkey Haemophilia Treatment Revenue (2018-2034) & (US$ Million)
Figure 88. Israel Haemophilia Treatment Revenue (2018-2034) & (US$ Million)
Figure 89. GCC Countries Haemophilia Treatment Revenue (2018-2034) & (US$ Million)
Figure 90. Haemophilia Treatment Value Chain
Figure 91. Haemophilia Treatment Production Process
Figure 92. Channels of Distribution (Direct Vs Distribution)
Figure 93. Distributors Profiles
Figure 94. Bottom-up and Top-down Approaches for This Report
Figure 95. Data Triangulation
Figure 96. Key Executives Interviewed